L01E Protein kinase inhibitors, antineoplastic and immunomodulating agents

Place in the ATC system

1. L Antineoplastic and immunomodulating agents 1,069 drugs
   1. L01 Antineoplastic agents 616 drugs
      1. L01E Protein kinase inhibitors, antineoplastic and immunomodulating agents 118 drugs
         1. L01EA BCR-ABL tyrosine kinase inhibitors 30 drugs
         2. L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors 16 drugs
         3. L01EC B-Raf serine-threonine kinase (BRAF) inhibitors 3 drugs
         4. L01ED Anaplastic lymphoma kinase (ALK) inhibitors 4 drugs
         5. L01EE Mitogen-activated protein kinase (MEK) inhibitors 5 drugs
         6. L01EF Cyclin-dependent kinase (CDK) inhibitors 7 drugs
         7. L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors 1 drug
         8. L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors 5 drugs
         9. L01EJ Janus-associated kinase (JAK) inhibitors 3 drugs
         10. L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors 3 drugs
         11. L01EL Bruton's tyrosine kinase (BTK) inhibitors 4 drugs
         12. L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors 3 drugs
         13. L01EX Other protein kinase inhibitors 30 drugs

Drugs in the class and its subclasses